Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will ...

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

Under the auspices of the Saudi Society of Rheumatology, Saudi Society of Dermatology and Dermatologic Surgery, Saudi ...

Revolutionizing Home and Commercial Cleaning with Aqueous Ozone Solutions that are hypoallergenic & eco-friendly ...

The global market for women’s digital health solutions is projected to grow significantly, reaching USD 9,618.9 million by ...

If not controlled with the above measures, your eczema might require prescription treatments like corticosteroids or even ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

A similar prevalence of acrylate sensitization was found among patients who were pre- and postimplantation of dental or orthopedic prostheses.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Occupational contact dermatitis was common among construction workers, with metals, epoxy resin, and rubber identified as common etiological sources.